Apatinib, Sintilimab, and Chemo for Intestinal Gastric Cancer
Part of Cancer, Digestive system clinical trials.
This phase 3 trial tests adding the targeted drug apatinib to a standard combination of sintilimab (immunotherapy) and chemotherapy (SOX regimen) given before surgery for a specific type of stomach or gastroesophageal junction cancer (intestinal type, HER2-negative). The goal is to see if the three-drug combination works better than the two-drug combination in shrinking the tumor and improving outcomes before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be a type called 'intestinal' (based on Lauren's classification) and be HER2-negative.
- The cancer should be locally advanced (stages cT2 to cT4, N0-N3, M0) and not spread to other parts of the body.
- Your age must be between 18 and 75 years old.
- You need to be in good physical condition (ECOG score of 0 or 1) and not have received any prior cancer treatment.
- Able to undergo surgery after preoperative chemotherapy and willing to provide tumor and blood samples.
- If you are able to become pregnant or get someone pregnant, you must agree to use effective birth control during the study and for 120 days after the last dose of study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of immunotherapy (cadonilimab) and chemotherapy before and after surgery for a specific type of advanced stomach or gastroesophageal junction cancer. It aims to see if adding this immunotherapy helps shrink tumors and improve outcomes.
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
This trial tests a combination of radiation, chemotherapy (SOX), and two targeted drugs (apatinib and camrelizumab) before and after surgery for stomach or gastroesophageal junction cancer. It aims to see if this approach is safe and effective.
This trial tests whether adding SHR-1701 (an immunotherapy) with or without apatinib (a targeted therapy) to standard chemotherapy before surgery can help treat gastric cancer. It is for people with stomach or gastroesophageal junction cancer that has spread to nearby lymph nodes but is still removable.
This trial tests whether adding an immunotherapy drug (adebrelimab) and a targeted therapy (apatinib) to standard chemotherapy helps shrink stomach cancer before surgery. It aims to improve outcomes for people with advanced stomach cancer that cannot be removed or has spread.
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
Hear when a new Neoadjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.